MedPath
HSA Approval

BAXTER-SODIUM CHLORIDE INJECTION USP 0.9% W/V

SIN16603P

BAXTER-SODIUM CHLORIDE INJECTION USP 0.9% W/V

BAXTER-SODIUM CHLORIDE INJECTION USP 0.9% W/V

September 14, 2022

BAXTER HEALTHCARE (ASIA) PTE LTD

BAXTER HEALTHCARE (ASIA) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantBAXTER HEALTHCARE (ASIA) PTE LTD
Licence HolderBAXTER HEALTHCARE (ASIA) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
General Sale List
HSA Singapore Classification

Formulation Information

INFUSION, SOLUTION

**Dosage and Administration** As directed by a physician. Dosage rate, and duration of administration are to be individualized and depend upon the indication for use, the patient’s age, weight, clinical condition and concomitant treatment, and on the patient clinical and laboratory response to treatment. When other electrolytes or medicines are added to this solution, the dosage and the infusion rate will also be dictated by the dose regimen of the additions. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Do not administer unless solution is clear and seal is intact. All injection in VIAFLEX plastic containers are intended for intravenous administration using sterile equipment. Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Before adding a substance or medication, verify that it is soluble and/or stable in water and that the pH range of Sodium Chloride Injection, USP is appropriate. The instructions for use of the medication to be added and other relevant literature must be consulted. After addition, check for a possible color change and/or the appearance of precipitates, insoluble complexes or crystals. Mix thoroughly when additives have been introduced. Do not store solutions containing additives. For single use only. Discard any unused portion.

INTRAVENOUS

Medical Information

**Indications and Usage** 0.9% Sodium Chloride Injection, USP is indicated as a source of water and electrolytes. 0.9% Sodium Chloride Injection, USP is also indicated for use as a priming solution in hemodialysis procedures.

**Contraindications** None known.

B05XA03

sodium chloride

Manufacturer Information

BAXTER HEALTHCARE (ASIA) PTE LTD

Baxter Healthcare Philppines, Inc.

Active Ingredients

Sodium Chloride

900mg per 100mL

Sodium chloride

Documents

Package Inserts

Baxter Sodium Chloride Injection USP 0.9% PI.pdf

Approved: September 14, 2022

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

BAXTER-SODIUM CHLORIDE INJECTION USP 0.9% W/V - HSA Approval | MedPath